BR112013012503A2 - análogos de bombesina marcados com 177 lutécio para radioterapia - Google Patents

análogos de bombesina marcados com 177 lutécio para radioterapia

Info

Publication number
BR112013012503A2
BR112013012503A2 BR112013012503A BR112013012503A BR112013012503A2 BR 112013012503 A2 BR112013012503 A2 BR 112013012503A2 BR 112013012503 A BR112013012503 A BR 112013012503A BR 112013012503 A BR112013012503 A BR 112013012503A BR 112013012503 A2 BR112013012503 A2 BR 112013012503A2
Authority
BR
Brazil
Prior art keywords
lutetium
radiotherapy
bombesin analogues
labeled bombesin
labeled
Prior art date
Application number
BR112013012503A
Other languages
English (en)
Portuguese (pt)
Inventor
Helmut Mäcke
Rosalba Mansi
Sandra Borkowski
Original Assignee
Piramal Imaging Sa
Uniersitätsspital Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Imaging Sa, Uniersitätsspital Basel filed Critical Piramal Imaging Sa
Publication of BR112013012503A2 publication Critical patent/BR112013012503A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112013012503A 2010-11-22 2011-11-21 análogos de bombesina marcados com 177 lutécio para radioterapia BR112013012503A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10075743 2010-11-22
PCT/EP2011/070553 WO2012069410A1 (en) 2010-11-22 2011-11-21 177lutetium-labeled bombesin analogs for radiotherapy

Publications (1)

Publication Number Publication Date
BR112013012503A2 true BR112013012503A2 (pt) 2016-11-08

Family

ID=45001762

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013012503A BR112013012503A2 (pt) 2010-11-22 2011-11-21 análogos de bombesina marcados com 177 lutécio para radioterapia

Country Status (16)

Country Link
US (1) US20140023585A1 (enExample)
EP (1) EP2643024A1 (enExample)
JP (1) JP2014500262A (enExample)
KR (1) KR20140053819A (enExample)
CN (1) CN103476434A (enExample)
AU (1) AU2011333948A1 (enExample)
BR (1) BR112013012503A2 (enExample)
CA (1) CA2818694A1 (enExample)
EA (1) EA026443B1 (enExample)
IL (1) IL226498A0 (enExample)
IN (1) IN2013MN01188A (enExample)
MX (1) MX2013005697A (enExample)
NZ (1) NZ610740A (enExample)
PH (1) PH12013501018A1 (enExample)
SG (1) SG190371A1 (enExample)
WO (1) WO2012069410A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100900A1 (en) * 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
PL2900279T3 (pl) 2012-09-25 2020-05-18 Advanced Accelerator Applications Usa, Inc. Antagonisty grpr do wykrywania, diagnostyki i leczenia raka grpr-pozytywnego
CN106039327A (zh) * 2016-06-14 2016-10-26 宁波益格爱生物科技有限公司 一种grpr靶向性分子探针及其制备方法
US20190358351A1 (en) * 2016-11-17 2019-11-28 Minerva Imaging Aps 177-lu labeled active site inhibited factor vii
US20250339567A1 (en) * 2019-12-19 2025-11-06 Technische Universität München Compounds with improved pharmacokinetics for imaging and therapy of cancer
EP4282439A1 (en) * 2022-05-23 2023-11-29 Erasmus University Rotterdam Medical Center Radioisotope labeled sstr2-agonists with linkers
CN117919452A (zh) * 2023-03-09 2024-04-26 中国科学院宁波材料技术与工程研究所 一种亚细胞器主动靶向成像探针及其制备方法
WO2025119203A1 (zh) * 2023-12-05 2025-06-12 烟台蓝纳成生物技术有限公司 一种异二聚体放射性核素偶联药物、制备及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100900A1 (en) * 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates

Also Published As

Publication number Publication date
US20140023585A1 (en) 2014-01-23
EA201300611A1 (ru) 2014-04-30
CA2818694A1 (en) 2012-05-31
NZ610740A (en) 2015-08-28
PH12013501018A1 (en) 2017-08-23
IN2013MN01188A (enExample) 2015-07-10
CN103476434A (zh) 2013-12-25
IL226498A0 (en) 2013-07-31
KR20140053819A (ko) 2014-05-08
WO2012069410A1 (en) 2012-05-31
JP2014500262A (ja) 2014-01-09
EA026443B1 (ru) 2017-04-28
MX2013005697A (es) 2014-08-01
AU2011333948A1 (en) 2013-06-06
SG190371A1 (en) 2013-06-28
EP2643024A1 (en) 2013-10-02

Similar Documents

Publication Publication Date Title
BR112013008017A2 (pt) análogos de carba-nucleosídeo 2-flúor substituídos para tratamento antiviral
TWM432515U (en) M1010701_3919
EP2537530A4 (en) RADIATION MEANS
TWM432980U (en) M1010701_3919
BR112013012503A2 (pt) análogos de bombesina marcados com 177 lutécio para radioterapia
TWM432503U (en) M1010701_3919
TWM432938U (en) M1010701_3919
BR112013011728A2 (pt) terapia de combinação com dexametasona
TWM432266U (en) M1010701_3919
TWM432676U (en) M1010701_3919
TWM432600U (en) M1010701_3919
ITCA20100013U1 (it) Spiedatore per anguille o capitoni
FR2964560B1 (fr) Stimulateur respiratoire
TWM432553U (en) M1010701_3919
TWM432355U (en) M1010701_3919
TWM432678U (en) M1010701_3919
TWM432713U (en) M1010701_3919
TWM432674U (en) M1010701_3919
TWM432625U (en) M1010701_3919
TWM432602U (en) M1010701_3919
TWM432801U (en) M1010701_3919
TWM432589U (en) M1010701_3919
TWM432577U (en) M1010701_3919
TWM432805U (en) M1010701_3919
TWM432544U (en) M1010701_3919

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI